X C Dong

Hybrid framework for rapid prediction, sparse flow field reconstruction, and boundary inversion of pollutant transport in urban lakes

X C Dong, Cun Zhou, Peng Liu, Yongqiang Luo et autres

cn (code pays fourni par la source)

Enhancing organic waste liquid incineration through oxygen-enriched combustion: Combustion performance, flow field evolution, and NOx emission trade-off at pilot scale

X C Dong, Zewu Zhang, Wenchao Mao, Junwei Luo et autres

cn (code pays fourni par la source)

Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O 6 ‐methylguanine–DNA methyltransferase glioblastoma: A single‐arm, phase 2 study

Bian Wu, Zhanjie Zhang, Hui Ma, J-M Huang et autres

BACKGROUND: -methylguanine-DNA methyltransferase (MGMT) glioblastoma derive minimal benefit from the standard temozolomide chemoradiotherapy, leaving an urgent need for more effective therapies. The objective of this phase 2 study was to evaluate the efficacy of anlotinib plus radiotherapy in this disease. METHODS: In …

cn (code pays fourni par la source)

UBE2O Drives Immune Evasion and Radioimmunotherapy Resistance in Lung Cancer by Degrading CDKL1 to Induce PD‐L1 Transcription

Huichan Xue, Xiaohua Jie, Zhiwei Liu, Ruoxin Fang et autres

ABSTRACT Resistance to radioimmunotherapy is one of the primary causes of treatment failure in lung cancer patients; however, the underlying mechanisms remain inadequately understood. In this study, we found that the E2/E3 hybrid ubiquitin enzyme UBE2O interacted with CDKL1, facilitating its ubiquitination …

cn (code pays fourni par la source)

Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.

Wei Li, L G Sun, Yan Yu, Sanxing Guo et autres

8558 Background: CS2009 is a novel PD-1/VEGF/CTLA-4 trispecific antibody. An ongoing phase 1/2 study is evaluating its safety, tolerability, PK, PD, and anti-tumor activity as a single agent and in combination with systemic treatment in patients (pts) with advanced solid tumors. This …

cn, au, hk, cz (code pays fourni par la source)

CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.

Charlotte Rose Lemech, Caicun Zhou, John J. Park, Bo Gao et autres

2521 Background: CS2009 is a first-in-class trispecific antibody targeting PD-1, VEGF and CTLA-4. Initial data from this phase 1 study showed a favorable safety profile and encouraging antitumor activity. Here, we report updated safety and efficacy results in 98 patients. Methods: This …

au, cn, hk, cz (code pays fourni par la source)

FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis

Xitang Li, J B Hu, Suping Hai, Peng Hu et autres

Metabolic dysfunction-associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined. Here, analyses of liver tissues and plasma from patients with MASLD, together with …

cn (code pays fourni par la source)

Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial

Pedro Rocha, Manish R. Patel, Yi-Long Wu, Jun Zhao et autres

Abstract Background: Brain metastasis (BM) is prevalent in extensive-stage small-cell lung cancer (ES-SCLC) and also a common cause for treatment failure. BM remains as an unmet need with limited treatment options available such as palliative radiotherapy. ZL-1310 is a novel antibody-drug conjugate …

es, us, cn, Éthiopie (code pays fourni par la source)

[Intracranial mesenchymal tumors with EWSR1-CREB1 fusion-positive: a clinicopathological study of three cases].

X C Dong, X Nie, Q Xia, Xiao⁃Xun Yang et autres

目的： 探讨原发性颅内间叶性肿瘤伴FET-CREB融合阳性型的临床及影像表现、病理形态学特征及分子遗传特点。 方法： 回顾性分析3例伴有FET-CREB融合阳性的原发性颅内间叶性肿瘤患者的临床病理特征、免疫表型、诊断、治疗及预后，并复习相关文献。 结果： 3例患者年龄分别为31、16、35岁，男性2例，女性1例，发病部位分别为右额部、左额颞部和右侧脑室，影像学均表现为界限清楚的占位性病变。镜下观察：组织学上共同特征表现为肿瘤边界清楚，背景可见多少不等的胶原化及黏液样改变，肿瘤细胞疏密不等，呈条索状或片状分布于黏液性间质中，部分病例可见血管丰富，肿瘤组织围绕血管生长，肿瘤细胞呈梭形、星芒状或上皮样。免疫组织化学染色显示肿瘤细胞均表达结蛋白及CD99，2例表达上皮细胞膜抗原，1例表达间变性淋巴瘤激酶及CD68，1例表达D2-40，Ki-67阳性指数5%~15%。分子表型：二代测序检测出1例EWSR1-CREB1基因融合及2例EWSR1-CREM基因融合。术后随访6~24个月，3例患者状态均良好，无复发及转移。 结论： FET-CREB融合阳性的原发性颅内间叶性肿瘤，诊断时应与影像特征及镜下形态相似的胶质瘤、脑膜瘤、孤立性纤维性肿瘤及其他伴有EWSR1基因融合的软组织肿瘤鉴别。.

hk, cn (code pays fourni par la source)